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Abstract
The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Syno-
vial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following failure of first-line 
anthracycline-based chemotherapy, several salvage options are available. We reviewed the safety and efficacy of gemcitabine/
docetaxel chemotherapy in two tertiary oncology centres. We identified patients treated with gemcitabine/docetaxel between 
2004 and 2016 in a UK and a US oncology centre using retrospective pharmacy and medical records. Treatment response, 
toxicity and outcome data were collected. Twenty one patients were treated with gemcitabine/docetaxel, the majority as a 
second- or third-line treatment for metastatic disease. The response rate was 5% with a median progression-free survival 
of 2 months (95% CI 1.3–3.7). Toxicities reported were as expected for this chemotherapy combination. Treatment was not 
discontinued due to toxicity. Gemcitabine/docetaxel chemotherapy shows little efficacy in synovial sarcoma and should not 
be offered to this patient group outside a clinical trial context.
Keywords Synovial sarcoma · Chemotherapy · Gemcitabine · Docetaxel
Introduction
Soft tissue sarcomas are a heterogeneous group of rare 
tumours of mesenchymal origin. They account for about 
1% of adult cancers and 15% of paediatric tumours. The 
mainstay of management for localized disease is complete 
surgical resection with or without (neo)adjuvant radiation. 
Despite optimal treatment, approximately 50% of patients 
with high-grade tumours will develop recurrent or meta-
static disease. The outcome of patients with metastatic soft 
tissue sarcoma is poor with a median overall survival of 
12–18 months. First-line chemotherapy for metastatic dis-
ease consists of an anthracycline-based regimen [1, 2]. Over 
the last few years, gemcitabine and docetaxel combination 
chemotherapy has emerged as an effective salvage sched-
ule, particularly in leiomyosarcoma and undifferentiated 
pleomorphic sarcoma [3, 4]. In addition, a number of other 
agents have recently been approved for treating advanced 
soft tissue sarcomas, including pazopanib, trabectedin, 
olaratumab and eribulin [5–8].
Synovial sarcoma is an uncommon type of sarcoma, rep-
resenting approximately 2.5% of all soft tissue sarcomas 
[9]. This tumour tends to occur in the extremities in adoles-
cents and young adults. It has a characteristic translocation 
t(X;18;p11.2;q11.2). Retrospective studies have suggested 
that this subtype is particularly sensitive to ifosfamide chem-
otherapy [10–12]. However, there are currently few data 
regarding the role of gemcitabine/docetaxel specifically in 
synovial sarcoma. Consequently, the aim of this study was to 
evaluate the efficacy and safety of this combination in syno-
vial sarcoma. We reviewed the use of gemcitabine/docetaxel 
in relapsed synovial sarcoma in patients from two tertiary 
cancer centres; at the Royal Marsden Hospital in London 
and at the Vanderbilt-Ingram Cancer Centre in Nashville, 
to assess any activity in this setting.
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Methods
Institutional Review Board approval was obtained prior to 
commencing the study. All patients with a histological diag-
nosis of synovial sarcoma treated with at least one cycle 
of gemcitabine/docetaxel chemotherapy between 2004 and 
2016 at the Royal Marsden Hospital and 2010 and 2016 at 
the Vanderbilt-Ingram Cancer Centre were identified using 
the unit database and pharmacy records. Data regarding 
baseline characteristics, treatment received, response assess-
ments and treatment toxicities were retrospectively collected 
from the electronic patient record. Progression-free survival 
was defined as time from first dose of gemcitabine/docetaxel 
to date of disease progression and overall survival as time 
from first dose of gemcitabine/docetaxel to death from any 
cause. Statistical and Kaplan–Meier analyses were per-
formed using GraphPad Prism version 7.0 (GraphPad Soft-
ware, La Jolla, California, USA).
An experienced soft tissue pathologist confirmed the 
diagnosis of synovial sarcoma in all cases. The presence 
of the t(X;18) translocation was also confirmed. Radio-
logical response was evaluated according to RECIST 1.1 
[13]. Response was evaluated after every 2 cycles of ther-
apy. Toxicity was graded according to CTCAE v4.03 [14]. 
Gemcitabine/docetaxel was administered intravenously on 
a three-weekly cycle with gemcitabine given at a dose of 
540–1000 mg/m2 (median 900 mg/m2) on Day 1 and 8 of 
the cycle and docetaxel given at 60–100 mg/m2 on Day 8 
(median 75 mg/m2). The majority of patients were treated 
according to the gemcitabine/docetaxel schedule detailed in 
Seddon et al. [15].
Results
Twenty-one patients were identified across both institutions 
(Table 1). The median age on commencing gemcitabine/
docetaxel was 42 years (range 20–61 years). Eleven of 21 
(52%) patients had Grade 3 synovial sarcoma. The major-
ity of patients had previous exposure to doxorubicin/ifosfa-
mide chemotherapy and 19/21 (90%) received gemcitabine/
docetaxel as a second- or third-line treatment in the locally 
advanced or metastatic setting.
Patients received at least one cycle of gemcitabine/
docetaxel chemotherapy. The median dose delivered was 
900 mg/m2 gemcitabine and 75 mg/m2 docetaxel, respec-
tively. Treatment was discontinued due to progressive dis-
ease or completion of 6 cycles of chemotherapy. Patients 
received a median of 3 cycles of treatment (range 1–6).
Response assessments were performed after a median of 
2 cycles of treatment for 17 patients and at the end of treat-
ment for all patients. At the interim response assessment, 
11/17 (65%) patients had disease progression on imaging 
(Fig. 1). At the end of the course of treatment, which ranged 
from 1.5 to 6 cycles of gemcitabine/docetaxel, 18/21 (86%) 
patients had progressive disease (Fig. 2). One patient had a 
partial response to treatment after 6 cycles. This patient had 
Table 1  Patient clinical 
characteristics Characteristic n (%)
Male 15 (71%)
Female 6 (29%)
Age (years)
 Median 42
 Range 20–61
Tumour grade
 1 0
 2 2 (10%)
 3 11 (52%)
 Unknown 8 (38%)
Treatment line in metastatic/
advanced setting
 First 1 (5%)
 Second 12 (57%)
 Third 7 (33%)
 Fourth 1 (5%)
Previous exposure to doxoru-
bicin/ifosfamide
 Yes 19 (90%)
 No 2 (10%)
Fig. 1  Response to gemcitabine/docetaxel chemotherapy at first 
response assessment. Red—progressive disease, green—stable dis-
ease, dashed lines—limits of stable disease i.e. − 30% and + 20% over 
baseline measurements
Medical Oncology (2018) 35:131 
1 3
Page 3 of 5 131
biopsy-proven metastatic synovial sarcoma with a known 
SS18/SSX1 fusion gene on molecular testing of the primary 
lesion. The median progression-free survival was 2.0 months 
(95% CI 1.3–3.7, Fig. 3a). Survival data were available for 
16/21 patients (76%, Fig. 3b). The median overall survival 
was 8.4 months (95% CI 6.7–15.1).
Toxicity data were available for 18/21 patients (86%). No 
patients discontinued treatment due to toxicity. The most 
frequently reported toxicities were fatigue, anaemia and 
diarrhoea (Table 2). No Grades 4–5 toxicities were reported.
Conclusion
Gemcitabine and docetaxel combination chemotherapy has 
emerged as an effective salvage schedule in advanced sar-
coma [3, 4, 16], particularly leiomyosarcoma and undifferen-
tiated pleomorphic sarcoma. Synovial sarcoma is generally 
regarded as a relatively chemosensitive sarcoma subtype, 
although radiological response assessments in synovial sar-
comas are particularly challenging [17]. However, there are 
few published data regarding gemcitabine/docetaxel in this 
subtype. Therefore, the aim of this study was to report the 
utility of this combination in synovial sarcoma. Our results 
suggest that gemcitabine/docetaxel has little efficacy with a 
response rate of 5% and median PFS of 2 months.
Recent data have shown no superiority for gemcitabine/
docetaxel over doxorubicin chemotherapy in the first-line 
setting [18]. In a study of 257 treatment-naïve patients with 
unresectable and metastatic soft tissue sarcoma, the over-
all response rate to gemcitabine/docetaxel was 20%. 11 
patients in this trial had synovial sarcoma; 4% of the patients 
receiving doxorubicin and 5% of those receiving gemcit-
abine/docetaxel. A planned analysis by histological subtype 
suggests that doxorubicin was more active than gemcitabine/
docetaxel in these patients [HR 4.15 (1.16–14.85)]. Con-
versely, the response rate observed in treatment-naïve leio-
myosarcoma and relapsed pre-treated metastatic leiomyosar-
coma to gemcitabine/docetaxel is approximately 25% [15, 
16].
Over the last few years, a number of agents have been 
approved for the treatment of metastatic soft tissue sar-
comas, including olaratumab, pazopanib and trabectedin. 
The Phase I/II trial of doxorubicin and olaratumab only 
included 3 synovial sarcoma patients [6]. Consequently, 
the activity of this agent in synovial sarcoma is unknown. 
This is likely due to the preference of most oncologists to 
treat synovial sarcoma patients with combination doxoru-
bicin/ ifosfamide, due to the efficacy of ifosfamide in this 
subtype [2, 10]. Consequently, it is difficult to comment on 
the efficacy of olaratumab in synovial sarcoma. In contrast, 
Fig. 2  Response to gemcitabine/docetaxel chemotherapy at end of 
treatment. Red—progressive disease, green—stable disease, blue—
partial response, dashed lines—limits of stable disease i.e. − 30% and 
+ 20% over baseline measurements
A
B
Fig. 3  Progression-free survival (a) and overall survival (b) of syno-
vial sarcoma patient cohort treated with gemcitabine/docetaxel chem-
otherapy [survival data available for 16/21 (76%) patients]
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there are retrospective data to suggest that trabectedin is 
active in this subtype [12]. The EORTC trials of pazopanib 
also demonstrate activity in synovial sarcoma [5, 19] as 
has the Phase II study of regorafenib [20] offering other 
therapeutic options in this subtype of soft tissue sarcoma.
In conclusion, our study suggests that patients with 
advanced synovial sarcoma should not routinely be offered 
gemcitabine/ docetaxel outside the context of a clinical 
trial. A number of other agents do have activity in this 
subtype, but further work is required to define the optimal 
sequence and identify novel therapies.
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